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Objective: Our objective was to perform a systematic review and meta-analysis on randomized 
controlled trials (RCTs) assessing the effect of curcumin on serum adiponectin concentration. 
Methods: We searched PubMed/Medline, Scopus, ISI Web of Science, Cochrane Library, and 
Google scholar databases up to April 2019. RCTs conducted among human adults studied the 
effects of curcumin on serum adiponectin concentrations as an outcome variable was included. 
The weighted mean differences (WMD) and standard deviations (SD) of change in serum 
adiponectin levels were calculated. The random effects model was used for deriving a summary 
of mean estimates with their corresponding SDs. 
Results: Out of 313 records, 6 trials that enrolled 652 subjects were included. The pooled 
results showed that curcumin supplementation significantly increased adiponectin 
concentrations in comparison with placebo (WMD: 0.82 Hedges’ g; 95% confidence interval 
(CI): 0.33 to 1.30, P˂0.001). Greater effects on adiponectin were observed in trials lasting ≤10 
weeks (WMD: 1.05 Hedges’ g; 95% CI: 0.64 to 1.45, P˂0.001). 
Conclusion: Curcumin significantly improves adiponectin concentrations. However, due to 
some limitations in this study, further studies are needed to reach a definitive conclusion about 
the effect of curcumin on the levels of adiponectin. 





Metabolic abnormalities and metabolic syndrome are a well-known cause of 
cardiovascular diseases, whilst insulin resistance is a prominent factor in the aetiology of 
metabolic syndrome (Qin et al. 2010). Adiponectin is a protein hormone with 244 amino acids 
that mediates numerous of metabolic processes, including glucose regulation and oxidation of 
fatty acids (Whitehead et al. 2006), and is an important adipokine produced by adipose tissues 
and is circulated in high concentrations. Moreover, adiponectin is regarded as a key regulator 
of insulin sensitivity, ameliorating inflammation of the tissue, recues systemic insulin 
resistance, and may be used as a predictor of cardiovascular disease (Rodina and Severin 2012). 
Furthermore, low levels of adiponectin have been found to be correlated with increased risk of 
diseases, including; diabetes, dyslipidaemia, hypertension and cardiovascular and metabolic 
syndrome (Rodina and Severin 2012). 
Nutraceuticals, or foods with known health-promoting benefits, have been identified as 
potential interventions for cardiovascular disease, attributable to their lipid-lowering effects 
(Cicero), amelioration of metabolic syndrome components (Patti), and improvements in 
vascular function and arterial blood pressure (Patti). Furthermore, attributable to the high costs 
and side effects associated with traditional pharmacotherapy, attention has been paid to the 
treatment through herbal medicine (Chuengsamarn, 2012). Curcumin has a pivotal role in 
reducing complications of diabetes and related metabolic disorders, attributed to antidiabetic, 
anti-inflammatory, and antioxidant properties and its purported ability to increase circulating 
adiponectin (Ali Hussain, 2002; Zhang, Fu, Gao, & Liu, 2013). Experimental and clinical 
studies have reported the effectiveness of curcumin supplementation on hyperlipidaemia and 
inhibiting atherosclerosis (Calabrese et al., 2008; Zheng et al., 2016). The results of some 
studies in animal models suggests that curcumin supplementation may decrease total 
cholesterol, triglycerides, and increase HDL‐C (WHO). Curcumin is asserted to regulate the 
secretion of inflammatory cytokines through proteins and enzymes signalling, resulting in 
reduced secretion of inflammatory cytokines, including interleukin‐6 (IL‐6), interleukin‐8 (IL‐
6), tumour necrosis factor‐α (TNF‐α), and monocyte chemoattractant protein‐1 (MCP‐1) (Babu 
& Srinivasan, 1997; Jain, Rains, Croad, Larson, & Jones, 2009). In a population of prediabetic 
participants, curcumin supplementation resulted in enhanced prevention of type II diabetes, 
improved β‐cell function, reduced insulin resistance, and higher levels of circulating 
adiponectin (Tan, 2004). Moreover, in a study of participants affected by obesity, with type II 
diabetes, Aggarwal & Harikumar, (2009) reported that curcumin supplementation resulted in 
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significant a reduction of high sensitivity C‐reactive protein (hs‐CRP), TNF‐α, and IL‐6 
(Aggarwal & Harikumar, 2009). Further, studies on rodent models suggest that curcumin may 
conceivably protect against vascular complications of diabetes, and other metabolic disorders, 
via its effects on Thioredoxin-interacting protein, intercellular adhesion molecule‐1, and nitric 
oxide synthase 2 enzyme expression (Na et al., 2014). 
Given the positive role adiponectin has on moderating a number of metabolic processes, 
the recently reported, positive, biological effects of curcumin supplementation, and the distinct 
lack of unifying consensus on the topic; our objective was to perform a systematic review and 
meta-analysis on randomized controlled trials (RCTs) assessing the effect of curcumin on 
serum adiponectin concentration 
Methods 
We conducted this meta-analysis according to Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines, which was adhered to during all stages of design, 
implementation, analysis, and reporting(1). 
 Data sources and search strategy 
We searched multiple electronic databases from the earliest available online indexing 
year through to April 2019, without language restrictions, including PubMed/Medline, Scopus, 
ISI Web of Science, Cochrane Library, and Google scholar. The keywords used in our search 
strategy were (“Curcumin” OR “Curcuma” OR “Curcuminoid” OR “Tumeric” OR 
“Turmeric”) AND (“adipokines” OR “adiponectin” OR “adipocytokines”). Reference lists 
from all related reviews and original primary studies were also screened to avoid missing any 
relevant articles. 
Study selection 
To accelerate the process of screening citations, the search results were imported into a 
bibliographic database and duplicates were removed automatically (EndNote X6; Thomson 
Reuters, New York). Subsequently, titles and abstracts screened by two independent authors 
(A.H and E.Gh) for relevance to the topic. Following this, full-texts of selected articles were 
retrieved and assessed for eligibility. Studies were included if they were randomized controlled 
trials of curcumin supplementation that evaluated adiponectin as an outcome. Studies were 
excluded if participants were children (<18 years) or if they had a concomitant intervention for 
which effects could not be separated; were of less than 2 weeks’ duration; did not report the 
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baseline and final values of outcome variables (or changes) in both curcumin and control 
groups; were letters, commentaries, reviews, ecological and animal studies, duplicate 
publication from the same study, or were published in non-English languages. Unpublished 
documents and grey literature, such as conference papers, dissertations, and patents were also 
excluded. Discrepancies were resolved by consensus and discussion with a third, independent, 
reviewer. 
Data extraction 
OF the included studies, two authors (A.H and E.Gh) independently extracted the 
following information into a data spread sheet: first author’s last name, publication year, study 
design, country, participants’ gender and mean age of subjects, type of study population, 
follow-up duration and dose of curcumin supplement. When the values for outcome variable 
were reported in different time points, data for the end of the trial were extracted. We emailed 
corresponding authors in cases of any unclear data. Any disagreements between the two 
reviewers were resolved in consultation with a third investigator (A.A). 
Quality assessment 
Two authors (A.H and E.Gh) independently evaluated the methodological quality of 
the included trials using the instrument developed by Jadad et al.(2). Briefly, this scale 
comprises 3 domains: 1) allocation concealment explanation (maximum of 2 points); 2) 
double-blinding explanation (maximum of 2 points); and 3) withdrawal explanation and 
follow-up completeness (maximum of 1 point). In total, a maximum score of 5 points can be 
achieved and studies with a Jadad score of <3 and ≥3 were considered as low and high-quality 
publications, respectively. Any discrepancies were discussed and resolved by a third 
investigator (M.P). 
Statistical analysis 
The difference in the mean values of adiponectin was calculated for all eligible studies 
and considered as the effect size. The net changes in adiponectin concentrations were estimated 
as the difference (curcumin minus control) between its changes (end values minus baseline) in 
the control group and the intervention group. Standard deviation (SD) of the mean difference 
was calculated using the following formula: SD = square root [(SD pre-treatment) 2 + (SD post-
treatment) 2 – (2 × R × SD pretreatment × SD post-treatment)](3). To ensure the meta-analysis 
was not sensitive to the selected correlation coefficient (R = 0.5), all analyses were repeated 
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using correlation coefficients of 0.2 and 0.8. Where a standard error (SE) was only reported, 
SD was estimated using the following formula: SD = SE × √n (n is the number of subjects in 
each group). The weighted mean difference (WMD) and its corresponding 95% confidence 
intervals (CIs), was calculated by conducting random effect model, taking the between study 
heterogeneity into account. The inconsistency index (I2) was used to quantify statistical 
heterogeneity in meta-analyses, and values greater than 50% were considered indicative of high 
heterogeneity. To find the sources of heterogeneity, subgroup analyses were performed based 
on the following categories: intervention dosage, duration of follow up, baseline BMI, and 
mean age of participants. Sensitivity analysis was used to explore the extent to which inferences 
might depend on a particular study or group of studies. In addition, plausible publication bias 
was specified visually by funnel plot and confirmed by the statistical evidence of Egger’s test. 
All statistical analyses were conducted using STATA, version 11.2 (Stata Corp, College 
Station, TX). P‐values less than 0.05 were considered as statistically significant. 
Results 
Study Selection Process 
From 313 potentially relevant citations identified in our structured searches, 229 
records were screened (after removing duplicates) and 13 full-text articles were assessed for 
eligibility. Next, 7 articles were excluded due to the following reasons: studied children (n=1) 
(4), administered curcumin in combination with other components (n=2) (5, 6), duplicate 
dataset (n=1) (7), published in non-English language (n=1) (8), and studies that did not provide 
sufficient data for outcomes (n=2) (9, 10). Finally, 6 trials (11-16) were included in this meta-
analysis. The flow chart for selecting studies is presented in Figure 1. 
Characteristics of the included studies 
Selected studies comprised a total of 652 participants in an intervention (322 
participants receiving curcumin treatment) or control groups (330 participants receiving 
placebo treatment). These articles were published between 2012 and 2019, which among them, 
three studies were performed in Iran (14-16), two in the Thailand (11, 13), and other study 
conducted in USA (12). The design of all the nominated trials was parallel. All records 
examined the effect of curcumin in both genders except for one study (12) that was restricted 
to men. Participants in these studies were patients with type 2 diabetes (11, 15), pre-diabetic 
subjects (13), obese men (12), and those with metabolic syndrome (14, 16). The mean age of 
the participants ranged from 27.1 to 59.37 years old and mean baseline BMI varied from 24.13 
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to 32.4 kg/m2. The range of dosage of curcumin supplementation varied from 200 to 1500 
mg/day. The duration of intervention was between 6 to 39 weeks in different studies. The 
general characteristics of the included studies are outlined in Table 1.  
According to Jadad scale, all studies had high quality (score ≥ 3). All studies were 
randomized trials, of them 4 records (11, 14-16) had properly explained the randomization 
procedure. In addition, all included studies had mentioned blindness whereas only four studies 
(12, 13, 15, 16) clearly described the blinding procedure. Details concerning a number of 
participants that dropped out and the reasons for this were reported in all studies. The general 
characteristics of the included studies are outlined in Table 1.  
Effect of curcumin supplementation on circulating adiponectin 
The individual trial results and the pooled estimate for the effect of curcumin 
supplementation on adiponectin are shown in Figure 2. Combining 6 effect sizes from 6 studies 
based on the random-effects model, we found that curcumin supplementation significantly 
increased adiponectin (WMD: 0.82 Hedges’ g; 95% CI: 0.33 to 1.30, P˂0.001) compared to 
the control group. However, the heterogeneity among the studies was high (I2=87.2%, 
P<0.001). To identify the sources of the between-study heterogeneity, subgroup analyses were 
conducted (Table 2). Mean age of study participants, baseline BMI, and curcumin dosage did 
not explain this heterogeneity. However, duration of intervention could explain the 
heterogeneity (I2=49.5%, P=0.13). In this analysis, we found that the effect of curcumin 
supplementation on circulating adiponectin was only significant in trials lasting ≤10 weeks 
(WMD: 1.05 Hedges’ g; 95% CI: 0.64 to 1.45, P˂0.001). Sensitivity analysis showed that the 
removal of each trial did not significantly influence the pooled effect of curcumin on 
adiponectin concentrations. The funnel plot was visually symmetrical (Figure 3) and the result 
of Egger’s test did not show any evidence of publication bias (P=0.91). 
Discussion 
Curcumin is a bioactive yellow-orange pigment of turmeric and extracted from the 
rhizomes of Curcuma longa Linn. (Zingiberaceae) (Ravichandran 2013). The therapeutic 
effects of curcumin and its analogues have been shown efficacious in a number of pathological 
conditions such as cancer (Mirzaei et al. 2016; Momtazi and Sahebkar 2016), osteoarthritis 
(Panahi et al. 2014), non-alcoholic fatty liver disease (Rahmani et al. 2016), anxiety and 
depression (Esmaily et al. 2015), pulmonary diseases (Panahi 2016) and ischemia/reperfusion 
injury (Sahebkar 2010). Given the purported capability of curcumin to elicit positive, biological 
8 
 
effects, and the known ability of adiponectin to protect against metabolic diseases, our 
objective was to perform a systematic review and meta-analysis on RCTs assessing the effect 
of curcumin on serum adiponectin concentration. In accord with this objective, the pooled 
results showed that curcumin supplementation significantly increased adiponectin 
concentrations in comparison with placebo; whilst greater effects on adiponectin were observed 
in trials lasting ≤10 weeks. 
Adiponectin is an anti‐inflammatory cytokine produced and secreted by adipose tissue. 
Adiponectin serum level reportedly has an inverse relationship with insulin resistance, 
dyslipidaemia, cardiovascular disease, and obesity (Tan, 2004; Yang et al., 2002); whilst 
decreases in adiponectin may resultantly increase the risk of atherosclerotic disease 
(Rothenbacher, Brenner, Marz, & Koenig, 2005). Adiponectin has a positive effect in reducing 
the risk of cardiometabolic disease, which is associated with lipid and glucose metabolism, 
anti‐inflammatory, and anti‐atherosclerotic properties (Esfahani, Movahedian, Baranchi, & 
Goodarzi, 2015). The results of some empirical studies have shown that supplementation of 
curcumin leads to a significant increase in serum adiponectin (Anand et al., 2007; Tan, 2004); 
whist in patients with metabolic syndrome, Panahi et al showed that supplementing with 1,000 
mg of curcumin daily for 8 months increased adiponectin and decreased leptin (Panahi et al., 
2016). In another example, consumption of 1,500 mg curcumin daily, for 9-months, in patients 
affected by pre-diabetes resulted in higher level of adiponectin (Tan, 2004). In the present 
study, we were able to confirm the veracity of a number of independent studies, highlighting 
that curcumin supplementation, particularly when consumed for longer than 10 weeks, ay 
significantly increase adiponectin levels, even when controlling for numerous biological and 
sociological variables. 
Insulin resistance is frequently defined as an impairment of insulin action on glucose, 
lipid and protein metabolism, and is closely associated with adipose tissue. Excessive visceral 
and subcutaneous adipose tissue causes adipocyte dysfunction which can result in 
inflammation through activation of JNK and NFқB. Such inflammation results in impaired 
adipokine secretion, manifest as decreased adiponectin and increased leptin levels (Castro; 
Shoelson). Adiponectin and leptin mediate insulin sensitivity through the AMPK (5´AMP-
activated protein kinase) pathway. AMPK is considered a ‘master switch’ capable of 
controlling the energy status in a cell, and its activation resultantly enhances β-oxidation and 
reduced fatty acid esterification to triglycerides (Vettor). Moreover, several empirical 
investigations have asserted that leptin-to-adiponectin ratio my conceivably serve as an 
effective index of insulin resistance and atherogenic risk in both diabetic and non-diabetic 
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populations (Finucane; Zalatel). Moreover, there are also reports demonstrating the association 
between leptin-to-adiponectin ratio and low-grade inflammation, carotid intima media 
thickness, arterial stiffness, time of first cardiovascular event and number of metabolic 
syndrome components (Kappelle). It has been shown that curcumin can influence numerous 
components of metabolic syndrome, including insulin resistance, low HDL-C, hypertension 
and obesity. This is due to the reaction of phytochemical materials with various molecular 
targets, such as transcription factors, receptors, enzymes, growth factors, hormones, cell 
adhesion molecules, lipoproteins and anti-oxidants, which are involved in the pathophysiology 
of metabolic syndrome (Panahi et al. 2014; Sahebkar 2014). Qu et al. (2008) reported that 
culturing curcumin at a concentration of 100 μg/ml increased adiponectin secretion and 
lessened IL-6 secretion in cultured human adipose tissues (Qu et al. 2008), whilst the effect of 
curcumin on the expression of adiponectin in rodent models has also been documented. In Bai 
et al. (2013), 64 mice were trichotomized (control group, a group receiving 50 mg of curcumin 
and a group receiving 250 mg of curcumin for 11 weeks), and in the group receiving 250 mg 
of curcumin, a significant increase in adiponectin levels was observed compared to the control 
group (Bai et al. 2013). In another study in rodent models, Weisberg et al. found that the 
consumption of 30 % dietary curcumin for 10 weeks increased the adiponectin level (Weisberg 
et al. 2008).  
As reported previously (Panahi; Panahi), and importantly, curcumin supplementation 
is safe. Moreover, curcumin has been approved by the United States FDA and considered a 
‘generally recognized as safe’ supplement, whilst its tolerability has been confirmed in several 
clinical studies. Therefore, owing to its safety and beneficial effects on several features of 
metabolic syndrome, and results of the present meta-analysis, curcumin may be suggested as a 
routine supplement for patients with metabolic syndrome, and other metabolic disorders.  
Strength and limitations 
The primary strength of this study was that this is the first meta-analysis to assess the 
impact of curcumin supplementation on adiponectin; and given the potential influence on 
clinical practice, this is a major finding. The evidence base, prior to this meta-analysis, was 
somewhat equivocal, and required a meta-analytical assessment, which we have provided. We 
demonstrated that there is sufficient evidence for curcumin supplementation to elicit 
significant, positive effects on adiponectin levels. A further strength of the current meta-
analysis is the accrual of the heterogeneous sample of participants, with a range of demographic 
status’, ethnicities and ages. We were also able to stratify analyses based on both duration of 
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supplementation and dosage, affording clinicians foresight into expected outcomes based on 
such information. 
Notwithstanding, the current study has some limitations worth considering. The 
analyses were not restricted to solitarily include patients of one type; although this permitted a 
larger number of studies and participants to be included for analyses, there may be disease 
specific modulators to the efficacy of curcumin, which requires further investigation. Some 
included trials were relatively small in sample size, and it has been asserted by Sterne et al. that 
it is conceivable for studies with small sample sizes to report bigger effect sizes in intervention 
arms than studies with larger participant pools (Sterne), nevertheless, this was out of the 
operational control of the meta-analysis. A further limitation of the present study was the 
paucity of eligible studies, highlighting the need for a greater number of high-quality RCT’s. 
Conclusion   
In conclusion, this systematic review and meta-analysis of randomized controlled 
clinical trials suggests that curcumin supplementation moderately increases circulating 
adiponectin. These findings support potential beneficial effects of curcumin supplementation 
on pathways related to adipocyte health and adiponectin metabolism. 
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Table 1. Characteristics of included trials 
 


























Patient Features Duration 
(weeks) 
 
Intervention Comparison Jadad 
score 
Chuengsamarn et al 
(2012) 
Thailand 201 Parallel 
(Double) 
Both 56.95 26.6 Pre-diabetic 
 
39 1500 mg/d curcuminods Placebo 
 
4 






Both 59.37 26.96 Type 2 diabetes   26 1500 mg/d curcuminods Placebo 
 
4 
Panahi et al 
(2016) 
Iran 100 Parallel 
(Double) 
Both 44.13 24.13 Metabolic syndrome 8 1000 mg/d curcumin Placebo 
 
4 
Salahshooh et al 
(2017) 
Iran 72 Parallel 
(Double) 
Both 38.2 31.1 Metabolic syndrome 6 1000 mg/d curcumin Placebo 
 
5 
Campbell et al 
(2019) 
USA 22 Parallel 
(Double) 





Adibian  et al 
(2019) 
Iran 44 Parallel 
(Double) 





Table 2. Subgroup analysis to assess the effect of curcumin supplementation on adiponectin level. 




95% CI I2 (%) P for 
heterogeneity 
P for between 
subgroup 
heterogeneity 
Mean age (year)      0.14 
˂50  3 0.87 0.20, 1.54 77.3 0.01  
≥50  3 0.78 0.00, 1.55 92.9 ˂0.001  
Mean baseline BMI (kg/m2)      0.47 
˂30 4 0.93 0.30, 1.56 91.3 ˂0.001  
≥30 2 0.55 -0.37,1.46 74.1 0.04  
Dose (mg/d)      0.14 
≤1000  3 0.87 0.20, 1.54 77.3 0.01  
˃1000 3 0.78 0.00, 1.55 92.9 ˂0.001  
Duration (week)      0.05 
≤10 3 1.05 0.64, 1.45 49.5 0.13  
˃10 3 0.59 -0.28, 1.47 93.6 ˂0.001  
effects model -Calculated by Random1 
BMI: body mass index 
 
 
 
 
 
 
